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-Tetrahydrocannabinol (THC) 3 and its 11-nor-9-carboxy-THC (THCCOOH) metabolite's urinary disposition are well characterized (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , although less is known about frequent cannabis smoking and phase II cannabis metabolites. Recent research documented extended excretion of cannabinoids in abstinent chronic daily smokers' blood and urine given THC's lipophilicity and large body stores (8 -9, 14 -15 ) . THC was detected in 1 cannabis smoker's hydrolyzed urine for 24 days; 11-hydroxy-THC (11-OH-THC) and THCCOOH were detected for at least 24 days (9 ) .
Accurately identifying recent cannabis intake is important for documenting potential impaired driving, accident causation, sports doping, and relapse during drug abuse treatment. Researchers have proposed models to identify new use in occasional (10 ) and frequent cannabis smokers (11 ) on the basis of total THCCOOH concentrations and time between 2 samples. Although these proposed models identified new use between 2 urine samples Ͼ24 h (occasional smok-ers' model) or Ͼ48 h apart (chronic frequent smokers' model), to our knowledge there is no model to accurately identify recent use from samples collected shortly after smoking, during the intoxication and impairment period. THC Ն1.5 g/L in occasional smokers' urine (following enzymatic hydrolysis) (4 ) and THC-glucuronide Ն2.3 g/L (equivalent to 1.5 g/L THC) (16 ) were suggested as markers of recent cannabis intake. To our knowledge, cannabidiol (CBD) and cannabinol (CBN) in urine have not yet been studied as recent use markers.
Phase II cannabinoid metabolite disposition has not been fully elucidated. Cannabinoids are mainly glucuronidated, with possible minor sulfation (17 ) . Studies documenting urinary THCCOOH and THCCOOH-glucuronide disposition used workplace (18 ) , random cannabis abstainers ' (19 ) or stability samples (20 ) , or they compared THCCOOH before and after hydrolysis (13, (21) (22) . Unconjugated THC and 11-OH-THC are not detected or detected in low concentrations (11-OH-THC only) in urine and require enzymatic or tandem enzymatic-alkaline hydrolysis to cleave glucuronides (19, (23) (24) . However, given the inability to definitively ensure complete hydrolysis, direct glucuronide analysis provides more accurate information regarding urinary metabolite disposition.
Here we simultaneously determined THC, 11-OH-THC, THCCOOH, CBD, CBN, THC-glucuronide, and THCCOOH-glucuronide concentrations in 14 frequent and 10 occasional smokers' urine following a single smoked 6.8% THC cigarette. We monitored cannabinoid phase I and II urinary metabolites for 30 h by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Materials and Methods

PARTICIPANTS
Healthy male and female study participants provided written informed consent to participate in this National Institute on Drug Abuse Intramural Research Program Institutional Review Board-approved study. Individuals were recruited by advertisements, flyers, and participant referrals. Participants were medically and psychologically evaluated to verify compliance with inclusion criteria: 18 -45 years old; self-reported mean frequency of cannabis smoking of Ͻ2ϫ/week (occasional smoker) or Ն4ϫ/week (frequent smoker) in the past 3 months; and a positive urine cannabinoid test for frequent smokers. Exclusion criteria included breastfeeding or pregnant, current medical condition or history of neurological illness, clinically significant adverse events associated with cannabis intoxication, Ͼ450 mL blood donation within 30 days of drug administration, clinically significant anemia; increased blood pressure or heart rate Ͼ100 bpm after 5-min rest, clinically significant electrocardiogram abnormality, or interest in drug abuse treatment, currently or within 60 days of study screening. Pregnancy tests were administered at screening and on study admission to women with reproductive potential.
STUDY DESIGN
Participants entered the secure research unit approximately 19 h before smoking to preclude intoxication at cannabis dosing. Participants smoked 1 [mean (SD)] 6.8% (0.2%) (54 mg) THC, 0.25% (0.08%) CBD, and 0.21% (0.02%) CBN cannabis cigarette ad libitum within 10 min. All urine was collected ad libitum from admission to 30 h after cannabis smoking into 250-mL polypropylene bottles (Thomas Scientific) and immediately refrigerated for Ͻ12 h. After volume determination, urine was aliquoted into 3.6-mL polypropylene Nunc cryotubes (Thomas Scientific), frozen, and analyzed within 24 h, except repeat analyses and dilutions completed within 48 h.
URINE CANNABINOID ANALYSIS
Urine samples were analyzed for THC, 11-OH-THC, THCCOOH, CBD, CBN, THC-glucuronide, and THCCOOH-glucuronide by LC-MS/MS according to a previously published method (25 ) . Linear ranges were 2-100 g/L for THC and CBN, 1-100 g/L for 11-OH-THC and CBD, 1-250 g/L for THCCOOH, 0.5-50 g/L for THC-glucuronide, and 5-500 g/L for THCCOOH-glucuronide [lowest number is limit of quantification (LOQ)]. Interassay (n ϭ 50) analytical bias and imprecision were 92.2%-102.2% and 5.2%-10.2%, respectively. Urine creatinine was measured on a Roche/Hitachi Modular D2400 analyzer by colorimetric assay based on the Jaffe reaction.
DATA ANALYSIS
Total cannabinoids excreted over time were calculated by multiplying cannabinoid concentration by urine void volume and adding analyte mass. Total THCCOOH (equivalent to unconjugated THCCOOH and THCCOOH-glucuronide) was calculated by adding molar THCCOOH and THCCOOH-glucuronide masses converted to THCCOOH concentrations. Creatinine-normalized concentrations were calculated by dividing cannabinoid concentration by creatinine concentration, providing concentrations in micrograms cannabinoid per gram creatinine (g/g). Several cutoffs were evaluated to determine adequate cutoffs for markers of recent use: 1, 2, and 5 g/L and 2 and 5 g/g for THCCOOH; 0.5, 1, 2, and 5 g/L and 2 and 5 g/g for THC-glucuronide; and 5 g/L for THCCOOH-glucuronide. Total THCCOOH was eval-uated at the 15-g/L cutoff set by the US Department of Health and Human Services (26 ) and at the 175-g/L decision limit recently announced (May 11, 2013) by the World Anti-Doping Agency (27 ) 
Results
HUMAN PARTICIPANTS
Fourteen healthy and frequent and 10 healthy and occasional smokers (17 males, 7 females), ages 19 -41 years, participated. Demographics are described in Table 1 of the Data Supplement that accompanies the online version of this report at http://www. clinchem.org/content/vol60/issue2.
URINE ANALYSIS
There were 414 urine voids between admission and 30 h after smoking; 412 were collected (participant B missed one predose urine void and participant H missed the first urine void postdose), and of these, 286 were collected postsmoking. Free THC, 11-OH-THC, CBD, and CBN were not detected.
There was a significant association between cannabis use group and positive urine cannabinoid test frequency in the 30 h after smoking ( 2 , 80.6, 170.2, 17.4, and 17.4 for THCCOOH, THC-glucuronide, THCCOOH-glucuronide, and total THCCOOH, respectively, all P values Ͻ 0.001). Frequent smokers' odds of having a positive cannabinoid urine test in the 30 h after smoking were 13.0, 107.1, 22.1, and 22.1 times higher than for occasional smokers for these analytes, respectively.
Creatinine-normalized and nonnormalized THCglucuronide concentrations peaked 0.6 -7.4 h after smoking (Table 1 and Fig. 1 ); THCCOOH and THCCOOH-glucuronide concentrations were highly variable (Table 1 ; also see online Supplemental Figs. 1 and 2). Maximal concentrations (non-and creatinine normalized) were significantly higher in frequent smokers for THCCOOH, THC-glucuronide, and THCCOOH-glucuronide (Table 2) ; participant H was excluded from THC-glucuronide comparison because the first urine void following smoking (likely t max ) was not collected. Nonnormalized THCCOOH and THCCOOH-glucuronide concentrations displayed high intra-and intersubject variability among frequent smokers. Creatinine-normalization did not improve intrasubject variability, except for THCCOOH-glucuronide in frequent smokers, and only then slightly reduced maximal concentration group differences, which remained significantly different ( Table 2) .
TIME OF LAST POSITIVE
The time of the last positive urine sample was determined for normalized and nonnormalized THCCOOH and THC-glucuronide in occasional smokers at various cutoffs but could not be determined in frequent smokers because of extended cannabinoid excretion ( Table 3 ). The last positive sample frequently occurred after the first negative sample, similar to other studies (5, 8 -9 ) , given urinary cannabinoid excretion variability ( Fig. 1 ; also see online Supplemental Figs. 1 and 2). Some participants had up to 6 negative samples between 2 THCCOOH-or THC-glucuronide-positive samples.
DETECTION RATES
The nonnormalized urine positivity rate (6-h time windows) was evaluated at each analyte's LOQ and for total THCCOOH at various cutoffs, including the LOQ and 15 and 175 g/L (Fig. 2) . At a 175-g/L cutoff, none of the occasional smokers' urine samples were positive, even immediately after smoking; only 50% and 3.9% of frequent smokers' urine samples were positive 0 -6 h and 24 -30 h after smoking, respectively.
DRUG MASS EXCRETED
Frequent smokers excreted significantly more total cannabinoid mass (moles) than occasional smokers due to previously self-administered cannabis (see online Supplemental Table 2 ). Because occasional smokers had low or negative cannabinoid concentrations at admission, we calculated the %THC (molar percentage) in the cigarette excreted as each cannabinoid; 0.00032% (0%-0.0048%), 0.0037% (0.000024%-0.010%), 0.094% (0.011%-0.323%), and 0.096% (0.011%-0.33%) of THC moles present in the cannabis cigarette were excreted as THCCOOH, THC-glucuronide, THCCOOH-glucuronide, and total THCCOOH, respectively, in urine over 30 h postsmoking.
NEW AND RECENT CANNABIS USE PREDICTION MODELS
THCCOOH/THCCOOH-glucuronide and THCglucuronide/THCCOOH-glucuronide ratios were calculated, but these values were not effective as markers of recent cannabis smoking owing to high intra-and intersubject variability (see online Supplemental Fig. 3 ). Because the model for chronic daily cannabis smokers (11 ) requires that samples be collected Ͼ48 h apart, we could not evaluate it with our data set. The occasional smoker model has 2 algorithms: one with all samples used for modeling, and the other omitting samples collected in the first 24 h after smoking. Although developed for occasional smokers, these models were never tested with urinary THCCOOH from frequent smokers. With algorithm 1 (at the 95% limit and a 15-g/L total THCCOOH cutoff), 2222 urine pairs were evaluated. Diagnostic sensitivity, specificity, and efficiency were 29.1%, 93.9%, and 65.8% for frequent smokers and 100%, 91.4%, and 92.7%, for occasional smokers, respectively. With algorithm 2 (excluding samples collected within 24 h of self-reported or controlled smoking), frequent smokers were not evaluated because all but participants F and G smoked the previous day, providing too few true positives for adequate method evaluation. In occasional smokers, 21 paired-positive urine samples had a diagnostic sensitivity, specificity, and efficiency of 100%.
These models require that urine samples be collected before and after new cannabis use, as would occur in routine urine monitoring in drug treatment, parole, or workplace settings. The models cannot be used to identify recent smoking in samples collected shortly after smoking, as would be the case when documenting impaired driving, new use in residential treatment facilities, or accident investigations and for incompetition prohibited drugs in sports. Therefore, we evaluated THC-glucuronide increases immediately after smoking and creatinine-normalized THCglucuronide in consecutive urine samples as a marker of recent use. All 14 frequent smokers and 10 occasional smokers were included in initial exploratory analysis for markers of recent use to evaluate multiple criteria (Table 4) Phase I and II Urinary Cannabinoids Disposition within 6 h of first sample collection with the best diagnostic sensitivity and efficiency.
Discussion
To our knowledge, these are the first urinary THC, 11-OH-THC, THCCOOH, CBD, CBN, THC-glucuronide, and THCCOOH-glucuronide concentration data following controlled cannabis smoking in frequent and occasional smokers with simultaneous direct analysis by LC-MS/MS. Only THCCOOH, THC-glucuronide, and THCCOOH-glucuronide were detected. 11-OH-THC, CBD, and CBN could be present as glucuronide or sulfate conjugates, but commercial conjugated standards are unavailable and thus could not be monitored in our method. Tandem enzymaticalkaline hydrolysis increased unconjugated 11-OH-THC and CBD concentrations (19, 23, 28 ) ; however, quantification following hydrolysis is not as precise as direct analytic measurement, given possible hydrolysis variability. Frequent smokers were 85.7% African American, whereas occasional smokers were 30.0% African American. To our knowledge, there are no studies examining racial differences in cannabinoid metabolism and disposition. THC is metabolized to 11-OH-THC through CYP2C9 (29 ) . Compared to American Africans, American whites have higher frequencies of CYP2C9*2 and CYP2C9*3 variant alleles, which exhibit decreased activity compared to the wild-type CYP2C9*1 (30 ) . Therefore, racial differences in CYP2C9 alleles could potentially confound the observed difference in smoker groups. However, previous research extensively documents extended excretion of cannabinoids in frequent smokers; therefore, we believe that the higher urinary cannabinoid concentrations in frequent smokers are caused by their greater previous cannabis exposure. Male percentages were similar between groups (71% and 70% in frequent and occasional smokers, respectively). Previous research documented no differences between male and female cannabis smokers (31 ). We are not aware of any studies that have examined the effects of age on cannabinoid metabolism. Although occasional smokers were significantly older (median age 33.0 years) than frequent smokers (median age 24.8 years), we do not believe that this age difference would result in clinically significant differences in cannabinoid metabolism and excretion.
THCCOOH AND THCCOOH-GLUCURONIDE
Nonnormalized THCCOOH and THCCOOHglucuronide concentrations exhibited large intra-and intersubject variability; only THCCOOH-glucuronide variability was reduced with creatinine normalization (see online Supplemental Figs. 1and 2) . We hypothesize that at lower concentrations, such as those of THCCOOH, minor analyte concentration fluctuations represent a larger overall percentage of the concentration; thus, overall variability might not be compensated for by creatinine normalization. However, differences in renal filtration, secretion, and/or reabsorption profiles cannot be ruled out. Determination of renal clearance rates for all cannabinoid analytes and creatinine is required to further evaluate the impact of creatinine-normalization. In occasional smokers creatinine-normalized and nonnormalized THCCOOH and THCCOOHglucuronide concentrations increased after smoking when present. No substantial increase was noted in frequent smokers because most THCCOOH and THCCOOH-glucuronide originated from prior selfadministered cannabis, masking increases from a single smoked dose. THCCOOH-glucuronide concentrations were much higher than THCCOOH concentrations in both groups (Table 1) . Most immunoassays and screening tests target THCCOOH and have unknown glucuronide cross-reactivity; the only assay for which cross-reactivity was documented (Alere TM ) had a reported cross-reactivity of 50%, possibly explaining the occurrence of some FN screening tests.
Nonnormalized, unconjugated THCCOOH concentrations in this study were much lower than previously reported, except for those reported by Kelly 
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and THCCOOH-glucuronide of 66 (72) and 1580 (1564) g/g, 9 (7) and 602 (545) g/g, and 3 (2) and 139 (92) g/g in frequent (several times/day), moderate (once/week to once/day), and occasional smokers (less than once/week), respectively, following direct analysis. Whereas Felli et al. and Skopp et al. stored samples at Ϫ20°C for unspecified time frames, Weinmann et al. did not report storage conditions. THCCOOH-glucuronide readily hydrolyzes to THCCOOH, producing up to 1-and 10-fold increases from baseline THCCOOH concentrations following 2-day storage at 4°C and 20°C, respectively; THC-COOH and THCCOOH-glucuronide were stable for at least 15 days at Ϫ20°C (20 ) . In our study, all samples were immediately refrigerated, frozen within 12 h, and analyzed on site generally within 24 h, minimizing THCCOOH formation during shipping or storage and possibly explaining our lower THCCOOH concentrations. Previous work documented acceptable stability of these cannabinoids following 3 freeze-thaw cycles (25 ) .
Total THCCOOH concentrations were consistent between our study and previously published studies. It is unclear from these data how long THCCOOH can be detected in frequent smokers' urine because urine collection extended only 30 h postdose, when 62% of frequent smokers' nonnormalized THCCOOH was Ն1.2 g/L. Skopp et al. documented nonnormalized THCCOOH in frequent smokers (cannabis consumption several times/day) for at least 10 days (LOQ ϭ 2 g/L) (19 ) . However, initial THCCOOH concentrations were much higher in those participants compared to our study population. For occasional smokers, only 60% were ever THCCOOH positive, and all but 2 were negative in their last urine sample. One participant with a positive last sample had 5 THCCOOH-negative urine samples before the positive sample at 30 h. The presence of THCCOOH in 62% of frequent smokers for more than 30 h and its low prevalence in occasional smokers precludes THCCOOH's use as a marker of recent use in either group. 
THC-GLUCURONIDE
Two reports documented THC-glucuronide analysis (16, 19 (19 ) . In our study, THC-glucuronide concentrations peaked immediately after smoking, returning to baseline concentrations within approximately 10 h (Fig. 1) , explaining the lower detection rates and concentrations in random urine samples from Skopp et al. In creatinine-normalized samples, participant J exhibited an unusual increase in normalized THC-glucuronide concentrations before smoking that did not occur in his noncreatinine normalized samples; this increase was an artifact of a low urine creatinine concentration (11 mg/dL). Following its peak in urine, THC-glucuronide concentration paralleled its rapid decrease in plasma after smoking (32 ) .
Other authors suggest that nonnormalized THCglucuronide Ͼ2.3 g/L could differentiate incompetition from out-of-competition cannabis use (16 ) . However, at our 2-and 5-g/L cutoffs, the time of last positive was Ͼ30 h in some frequent smokers, negating the utility of THC-glucuronide as a general marker of recent use. In frequent smokers, THCglucuronide exceeded 0.5 g/L in all 14 smokers' last urine samples, precluding determination of time of last detection. We previously found extended unconjugated THC excretion (Ն2.5 g/L, up to 24 days) in chronic daily smokers' urine samples following tandem enzymatic-alkaline hydrolysis (9 ). Because we found no unconjugated THC in urine in the present study, total THC detected in the previous study was most likely liberated from THC-glucuronide following hydrolysis. In occasional smokers, THC-glucuronide was detected for 1.3-23.2 h at the method's LOQ and for 1.3-7.1 h with a 1-g/L cutoff. Some occasional smokers were negative by 2 h and others had THCglucuronide-negative urine samples interspersed between 2 positive samples within 20 h after smoking. Therefore, THC-glucuronide presence can be used as an inclusionary, but not exclusionary, marker of recent use, if there is clear evidence of occasional consumption.
MODEL OF RECENT USE
We describe here the utility of monitoring THCglucuronide in consecutive urine samples to document cannabis smoking within 6 h (Table 4) , a period of time closely mirroring the window of acute cannabis psychomotor impairment (33 ) . Previous models used creatinine-normalized urine samples to evaluate if new cannabis smoking occurred between 2 samples bracketing potential cannabis use. To our knowledge, there are no methods of documenting recent use from samples collected shortly after smoking and without a prior baseline concentration, as would be the case when documenting potential impaired driving, new use in residential treatment facilities, accident investigations, and prohibited in-competition drug use in sports. When an individual is in custody or supervised for an extended period of time, the governing agency may be able to collect multiple urine samples. By collecting consecutive samples and setting new use criteria of absolute %difference between the 2 consecutive samples of Ն50% and a creatinine-normalized concentration of Ն2 g/g in the first of the consecutive samples, we were able to identify recent cannabis smoking within 6 h of the first urine collection with high efficiency. This model had lower efficiency in occasional smokers because there were fewer consecutive positive THCglucuronide samples. A criterion of Ն2 g/g in the first of the consecutive samples was used to minimize FP that may occur given variability in urinary concentrations during extended excretion in frequent smokers. By using the absolute Ն50% difference, the model allowed collection during the initial THC-glucuronide excretion phase, when THC-glucuronide may still be rising. There were 4.2% FP predictions in frequent smokers and 7.7% in occasional smokers. There were 1.0% FN predictions in frequent smokers and 15.4% in occasional smokers. FP and FN results were distributed evenly across individuals. All FN had absolute %differ-ences of Ͻ50%; however, lowering the criteria to a %difference of Ն40% increased FP. In this proposed model, FP occurred when recent use (Ͻ6 h) was predicted but actual smoking occurred 6.4 -11.5 h before the first of consecutive sample collections. Although considering only %difference has similar efficiency, the possibility of FP due to natural urinary concentration variability is higher. Consecutive urine samples were collected 0.3-8.3 h apart; the time between urine collections did not affect the model. Further model evaluation with a second set of data is needed.
We also documented here simultaneous THCCOOH, THC-glucuronide, and THCCOOHglucuronide analysis in frequent and occasional smokers following controlled smoked cannabis. THCCOOH, THC-glucuronide, and THCCOOHglucuronide concentrations were significantly higher in frequent than occasional smokers. Furthermore, a creatinine-normalized THC-glucuronide absolute % difference Ͼ50% between 2 consecutive urine samples, with the first of the consecutive samples Ն2 g/g, may be used as a marker of recent smoking within 6 h of the first sample collection in frequent smokers. These data will improve urinary cannabinoid interpretation in clinical, drug treatment, law enforcement, sports doping, and workplace drug testing programs.
